| Unique ID issued by UMIN | UMIN000048635 |
|---|---|
| Receipt number | R000055404 |
| Scientific Title | Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples |
| Date of disclosure of the study information | 2022/08/09 |
| Last modified on | 2024/11/14 19:52:39 |
Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples
Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples
Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples
Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples
| Japan |
Acquired Hemophilia A
| Hematology and clinical oncology | Pediatrics |
Others
NO
To indicate the Japanese acquired hemophilia A (AHA) patients' reactivity of TAK-672 by measuring anti-recombinant porcine FVIII (rpFVIII) antibody titer in the Japanese AHA patients' plasma and calculating the cross-reactivity
Others
Not applicable
Others
Others
Not applicable
Cross-reacting against rpFVIII in acquired hemophilia A
Not applicable
Observational
| Not applicable |
| Not applicable |
Male and Female
The plasma samples of patients with AHA who were diagnosed and the informed consent was obtained from in the form of opt-out at Nara Medical University
Not applicable
15
| 1st name | Keiji |
| Middle name | |
| Last name | Nogami |
Nara Medical University
Department of Pediatrics
634-8521
840, Shijo-cho, Kashihara, Nara, 634-8521, Japan
0744-29-8881
pediatrics@naramed-u.ac.jp
| 1st name | Yasuo |
| Middle name | |
| Last name | Miyaguchi |
Takeda Pharmaceutical Company Limited.
Japan Medical Office
103-8668
1-1, Nihonbashi-Honcho, 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan
070-4921-7966
yasuo.miyaguchi@takeda.com
Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Company Limited.
Profit organization
Nara Medical University Ethics Committee
840, Shijo-cho, Kashihara, Nara, 634-8521, Japan
0744-22-3051
ino_rinri@naramed-u.ac.jp
NO
| 2022 | Year | 08 | Month | 09 | Day |
https://link.springer.com/article/10.1007/s12185-024-03854-5
Published
https://link.springer.com/article/10.1007/s12185-024-03854-5
16
Nine of 16 plasma samples (56.3%) had positive pFVIII-INH, with a median cross-reactivity of 1.2%. FVIII activity (FVIII:C) was restored to > 100% in all samples upon spiking with rpFVIII.
| 2024 | Year | 11 | Month | 14 | Day |
| 2024 | Year | 10 | Month | 30 | Day |
Patients with Acquired Hemophilia A (PwAHA)
Previously collected and stored plasma samples from Japanese PwAHA were used for this study. Patients had agreed to future use of their plasma samples by Nara Medical University, and measurements for this study were performed after website opt-out in compliance with the Japanese Ethical Guidelines. Plasma samples were obtained between January 2011 and April 2022 and stored at below -80 degrees Celsius until the assay measurements.
N/A
Cross-reactivity to rpFVIII (anti-pFVIII inhibitor titer/anti-humman FVIII inhibitor titer)
Coagulation Potential of Patient Plasma after spiking rpFVIII (FVIII activity, thrombin generation assay, clot waveform analysis)
Main results already published
| 2022 | Year | 05 | Month | 19 | Day |
| 2022 | Year | 08 | Month | 03 | Day |
| 2022 | Year | 08 | Month | 26 | Day |
| 2023 | Year | 03 | Month | 31 | Day |
Not applicable
| 2022 | Year | 08 | Month | 09 | Day |
| 2024 | Year | 11 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055404